{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:12:42Z","timestamp":1790039562470,"version":"4.0.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1097\/cmr.0b013e32834defd6","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T07:32:26Z","timestamp":1324020746000},"page":"92-95","source":"Crossref","is-referenced-by-count":12,"title":["The RET G691S polymorphism is a germline variant in desmoplastic malignant melanoma"],"prefix":"10.1097","volume":"22","author":[{"given":"Jodie","family":"Barr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol M.","family":"Amato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kounalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210129","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO;2-E","article-title":"Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival.","volume":"42","author":"Amer","year":"1978","journal-title":"Cancer"},{"key":"R2-12-20210129","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/sj.bjc.6605622","article-title":"Determinants of survival in patients with brain metastases from cutaneous melanoma.","volume":"102","author":"Staudt","year":"2010","journal-title":"Br J Cancer"},{"key":"R3-12-20210129","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1038\/sj.onc.1206460","article-title":"Development of melanocyte precursors from the vertebrate neural crest.","volume":"22","author":"Dupin","year":"2003","journal-title":"Oncogene"},{"key":"R4-12-20210129","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00000478-197908000-00002","article-title":"Neurotropic melanoma. A variant of desmoplastic melanoma.","volume":"3","author":"Reed","year":"1979","journal-title":"Am J Surg Pathol"},{"key":"R5-12-20210129","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1097\/00000478-199612000-00008","article-title":"Desmoplastic and spindle-cell malignant melanoma. An immunohistochemical study.","volume":"20","author":"Longacre","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"R6-12-20210129","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1128::AID-CNCR11>3.0.CO;2-7","article-title":"Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients.","volume":"83","author":"Quinn","year":"1998","journal-title":"Cancer"},{"key":"R7-12-20210129","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00000478-198905000-00003","article-title":"Desmoplastic malignant melanoma and its variants A study of 45 cases. .","volume":"13","author":"Jain","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"R8-12-20210129","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000094087","article-title":"Evolution of the GDNF family ligands and receptors.","volume":"68","author":"Airaksinen","year":"2006","journal-title":"Brain Behav Evol"},{"key":"R9-12-20210129","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbrc.2010.01.136","article-title":"Beyond the cell surface: new mechanisms of receptor function.","volume":"396","author":"Ibanez","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"R10-12-20210129","first-page":"305","article-title":"Developmental expression of the RET protooncogene.","volume":"5","author":"Avantaggiato","year":"1994","journal-title":"Cell Growth Differ"},{"key":"R12-12-20210129","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12022-007-0009-5","article-title":"RET signaling in endocrine tumors: delving deeper into molecular mechanisms.","volume":"18","author":"Lai","year":"2007","journal-title":"Endocr Pathol"},{"key":"R13-12-20210129","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11102-006-0263-4","article-title":"RET and neuroendocrine tumors.","volume":"9","author":"Murakumo","year":"2006","journal-title":"Pituitary"},{"key":"R14-12-20210129","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1007\/s00018-004-4276-8","article-title":"Dysfunction of the RET receptor in human cancer.","volume":"61","author":"Santoro","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"R15-12-20210129","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1210\/jc.2003-031898","article-title":"RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population.","volume":"89","author":"Elisei","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-12-20210129","doi-asserted-by":"crossref","first-page":"11536","DOI":"10.1158\/0008-5472.CAN-05-2843","article-title":"The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling.","volume":"65","author":"Sawai","year":"2005","journal-title":"Cancer Res"},{"key":"R17-12-20210129","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1038\/onc.2009.164","article-title":"Functional RET G691S polymorphism in cutaneous malignant melanoma.","volume":"28","author":"Narita","year":"2009","journal-title":"Oncogene"},{"key":"R19-12-20210129","doi-asserted-by":"crossref","first-page":"29230","DOI":"10.1074\/jbc.M703461200","article-title":"Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.","volume":"282","author":"Plaza-Menacho","year":"2007","journal-title":"J Biol Chem"},{"key":"R20-12-20210129","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","article-title":"Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.","volume":"27","author":"Hauschild","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00008390-201202000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:33:15Z","timestamp":1786048395000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00008390-201202000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/cmr.0b013e32834defd6","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}